SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations and institutional ownership.
Institutional and Insider Ownership
31.6% of SOPHiA GENETICS shares are held by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. 4.9% of SOPHiA GENETICS shares are held by insiders. Comparatively, 2.2% of Valion Bio, Inc. Common Stock shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for SOPHiA GENETICS and Valion Bio, Inc. Common Stock, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SOPHiA GENETICS | 1 | 1 | 3 | 0 | 2.40 |
| Valion Bio, Inc. Common Stock | 1 | 0 | 0 | 0 | 1.00 |
Profitability
This table compares SOPHiA GENETICS and Valion Bio, Inc. Common Stock’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SOPHiA GENETICS | -44.48% | -62.74% | -21.85% |
| Valion Bio, Inc. Common Stock | N/A | -138.10% | -63.67% |
Volatility & Risk
SOPHiA GENETICS has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.82, meaning that its share price is 82% more volatile than the S&P 500.
Valuation & Earnings
This table compares SOPHiA GENETICS and Valion Bio, Inc. Common Stock”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SOPHiA GENETICS | $77.27 million | 6.57 | -$79.00 million | ($0.52) | -11.63 |
| Valion Bio, Inc. Common Stock | $780,000.00 | 1.52 | -$8.88 million | ($6.68) | -0.04 |
Valion Bio, Inc. Common Stock has lower revenue, but higher earnings than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.
Summary
SOPHiA GENETICS beats Valion Bio, Inc. Common Stock on 10 of the 14 factors compared between the two stocks.
About SOPHiA GENETICS
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.
About Valion Bio, Inc. Common Stock
Tivic Health Systems Inc. operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, such as BestBuy and FSAStore and through distributors. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.
Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.
